Precision proteomics broadens MultiOmics repertoire and enables biomarker discovery
Olink Proteomics is a Swedish company with strong global presence, that enables high-plex protein biomarker discovery and development. Olink’s platform currently has the ability to robustly measure ~5,400 analytes. It’s been used in different settings due to its scalability and actionability such as in the elucidation of pathways and mechanisms of drug action, as a screening tools for identifying signatures/biomarkers with a prognostic/predictive significance as well as to safety and toxicity studies, drug target selection and differentiation. Due to the fact that the protein library, which continuously expands, covers all major biological pathways the applications are in numerous disease areas, such as, Cardiology, Diabetes Immuno-oncology and Neurology.

In this scientific seminar they will go through a series of case studies elucidating the power of their capabilities:
* How Olink technology enables biomarker identification, precision medicine and multiOmics approaches.
* Examples of Olink technology applied in specific human disease areas.
Date: 2 May 2024, 12:00 (Thursday, 2nd week, Trinity 2024)
Venue: Zoom
Speaker: Dr Sarantis Chlamydas (Olink Proteomics)
Organising department: Divisional Office (MSD)
Organisers: Betina Nair (University of Oxford), Sheena Lee (MSD Business Partnerships Office), Medical Sciences Division Business Partnerships Office (University of Oxford)
Organiser contact email address: sheena.lee@medsci.ox.ac.uk
Host: Betina Nair (University of Oxford)
Part of: Industry Insight Seminar Series
Booking required?: Required
Booking url: https://forms.office.com/e/bhmYq6An7s
Cost: Free
Audience: Members of the University of Oxford and the Biotech/Pharma industry
Editor: Sheena Lee